Veradermics, Inc 8-K

What Happened
Veradermics, Inc. announced its quarterly financial results for the quarter ended March 31, 2026 via a press release dated May 12, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8‑K (Item 2.02 — Results of Operations and Financial Condition). The filing was signed by CEO Reid Waldman, M.D.

Key Details

• Filing date: May 12, 2026 (Form 8‑K, Item 2.02).
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1; Interactive XBRL cover page included as Exhibit 104.
• Form 8‑K signed and submitted by CEO Reid Waldman, M.D.

Why It Matters
This 8‑K signals Veradermics has publicly disclosed its most recent quarterly results; investors should read the attached press release (Exhibit 99.1) for revenue, earnings, cash position, and any management commentary. The 8‑K itself furnishes the release (rather than filing it), so follow‑up SEC filings (e.g., the company’s next 10‑Q) may provide audited or more detailed financial statements and reconciliations.